Drug Trial Radar · NCT04577352
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Dec 17, 2020
Primary completion
Apr 4, 2023
Study completion Oct 2, 2023
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale \[mFARS\]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
Conditions
- Friedreich Ataxia
Interventions
VatiquinoneDrug
Vatiquinone will be administered per dose and schedule specified in the arm.
PlaceboDrug
Placebo will be administered per schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis SetTime frame: Baseline, Week 72
- Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis SetTime frame: Baseline, Week 72
Locations
14 sites in 9 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
University of Florida
Gainesville, Florida
University of South Florida
Tampa, Florida
University of Iowa
Iowa City, Iowa
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Murdoch Children's Research Institute
Parkville, Victoria, Australia
University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology
São Paulo, Brazil
Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)
Montreal, Quebec, Canada
CHU Sainte-Justine
Montreal, Quebec, Canada
Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute)
Paris, France
Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE)
Tübingen, Germany
Ospedale Pediatrico Bambino Gesu' IRCCS
Roma, Italy
CBR Neurogenetic Research Clinic, University of Auckland
Auckland, New Zealand
Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.